N4 Pharma (N4P) Competitors GBX 0.65 -0.03 (-3.70%) As of 04:26 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitors N4P vs. CHLL, MXC, RGT, HELD, HLN, HIK, HCM, INDV, AMYT, and AGYShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Chill Brands Group (CHLL), Argent BioPharma (MXC), Argent BioPharma (RGT), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), and Allergy Therapeutics (AGY). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Chill Brands Group Argent BioPharma Argent BioPharma Hellenic Dynamics Haleon Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Allergy Therapeutics N4 Pharma (LON:N4P) and Chill Brands Group (LON:CHLL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Which has stronger earnings & valuation, N4P or CHLL? N4 Pharma has higher earnings, but lower revenue than Chill Brands Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioN4 Pharma£23.52K110.43-£1.08MN/AN/AChill Brands Group£624.19K0.00-£3.64M-£0.01N/A Does the media favor N4P or CHLL? In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled Chill Brands Group'saverage media sentiment score. Company Overall Sentiment N4 Pharma Neutral Chill Brands Group Neutral Is N4P or CHLL more profitable? N4 Pharma's return on equity of -82.39% beat Chill Brands Group's return on equity.Company Net Margins Return on Equity Return on Assets N4 PharmaN/A -82.39% -56.00% Chill Brands Group N/A -2,802.21%-44.64% Do insiders & institutionals have more ownership in N4P or CHLL? 0.2% of Chill Brands Group shares are owned by institutional investors. 18.0% of N4 Pharma shares are owned by insiders. Comparatively, 24.2% of Chill Brands Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor N4P or CHLL? N4 Pharma received 97 more outperform votes than Chill Brands Group when rated by MarketBeat users. However, 66.67% of users gave Chill Brands Group an outperform vote while only 65.61% of users gave N4 Pharma an outperform vote. CompanyUnderperformOutperformN4 PharmaOutperform Votes10365.61% Underperform Votes5434.39% Chill Brands GroupOutperform Votes666.67% Underperform Votes333.33% Which has more volatility and risk, N4P or CHLL? N4 Pharma has a beta of -0.37, indicating that its stock price is 137% less volatile than the S&P 500. Comparatively, Chill Brands Group has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. SummaryChill Brands Group beats N4 Pharma on 6 of the 10 factors compared between the two stocks. Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£2.60M£1.16B£5.39B£2.04BDividend Yield3.12%3.04%5.37%5.16%P/E Ratio-55.00129.7388.831,926.65Price / Sales110.432,916.701,282.26384,006.48Price / Cash2.2510.2536.6029.21Price / BookN/A3.264.963.08Net Income-£1.08M£152.21M£117.89M£183.60M7 Day Performance-16.60%0.23%2.75%3.09%1 Month Performance19.64%3.14%3.63%3.42%1 Year Performance-32.86%103.17%27.27%165.41% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.65-3.7%N/A-32.9%£2.57M£23,524.00-55.005CHLLChill Brands GroupN/AN/AN/AN/A£10.89M£624,187.00-215.007Positive NewsMXCArgent BioPharmaN/AN/AN/AN/A£9.65M£1.32M-13.255Gap UpRGTArgent BioPharmaN/AGBX 5.79-10.9%N/AN/A£3.10MN/A-24.12N/AGap DownHigh Trading VolumeHELDHellenic DynamicsN/AGBX 0.95flatN/AN/A£1.40MN/A0.00N/AHLNHaleon1.7904 of 5 starsGBX 369+0.5%GBX 415+12.5%+12.0%£33.36B£11.26B3,075.0025,408High Trading VolumeHIKHikma Pharmaceuticals1.9161 of 5 starsGBX 2,010+0.4%GBX 2,383.33+18.6%+7.9%£4.46B£3.02B3,092.319,100HCMHUTCHMEDN/AGBX 230-8.7%N/A+2.3%£1.97B£610.81M-5,750.001,760Gap DownHigh Trading VolumeINDVIndivior1.7412 of 5 starsGBX 939+2.8%GBX 1,650+75.7%-19.0%£1.21B£1.15B-1,173.751,000AMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 7.41-1.7%N/AN/A£353.46M£53.26M-123.50612News CoverageGap Up Related Companies and Tools Related Companies Chill Brands Group Alternatives Argent BioPharma Alternatives Argent BioPharma Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:N4P) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
